| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| 500mg |
Purity: ≥98%
| Targets |
Vasicine targets multiple pathways including bronchodilation through relaxation of bronchial smooth muscle, possibly mediated by beta-adrenergic receptor activation or phosphodiesterase inhibition. It also exhibits anti-inflammatory activity by inhibiting the production of pro-inflammatory mediators. The compound shows antimicrobial activity against various bacterial and fungal pathogens. Its antioxidant properties are mediated through free radical scavenging and modulation of antioxidant enzyme systems.
|
|---|---|
| ln Vitro |
In vitro, vasicine demonstrates bronchodilator activity by relaxing bronchial smooth muscle in isolated tissue preparations. It shows anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines and mediators. The compound exhibits antimicrobial activity against various bacterial and fungal strains. Specific IC₅₀ values for these activities are documented in the literature. Vasicine also shows antioxidant activity by scavenging free radicals and reducing oxidative stress in cell-based assays.
|
| ln Vivo |
In vivo, vasicine has been studied in animal models of respiratory disorders, including asthma and bronchitis. It shows bronchodilator and expectorant effects, improving respiratory function. The compound has been used in traditional medicine for the treatment of respiratory conditions. Its anti-inflammatory and antimicrobial activities contribute to its therapeutic effects in respiratory infections and inflammatory airway diseases. Clinical studies have been conducted to evaluate its efficacy in respiratory disorders.
|
| Enzyme Assay |
Bronchodilator activity is assessed using isolated tracheal or bronchial smooth muscle preparations. Tissues are mounted in organ baths, and contractile responses to various agonists are measured. Vasicine is tested at various concentrations, and EC₅₀ values for relaxation are calculated. Anti-inflammatory assays measure inhibition of cytokine production in activated immune cells. Antimicrobial susceptibility testing is performed using broth microdilution methods. Antioxidant activity is assessed by DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
In vitro cellular assays use bronchial epithelial cells, smooth muscle cells, or immune cells. Cells are treated with vasicine at various concentrations. Bronchodilator activity is assessed by measuring relaxation of pre-contracted smooth muscle cells. Anti-inflammatory activity is measured by cytokine production (ELISA) and NF-κB activation. Antimicrobial activity is assessed using bacterial or fungal cultures with MIC determination. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of asthma (ovalbumin-induced airway hyperresponsiveness), bronchitis, and other respiratory disorders. Vasicine is administered orally or intraperitoneally. Endpoints include airway resistance, bronchoalveolar lavage inflammatory cell counts, cytokine levels, and histopathological assessment of lung tissues. Expectorant activity is assessed by measuring mucus production and clearance. Pharmacokinetic studies are conducted to determine plasma concentrations.
|
| ADME/Pharmacokinetics |
Vasicine (peganine) is a quinazoline alkaloid. Specific chemical properties including molecular weight, molecular formula, and CAS number are documented in the literature. The compound is typically stored at -20°C and protected from light. It is soluble in DMSO and other organic solvents. Specific pharmacokinetic parameters are documented in the literature from preclinical and clinical studies. It is metabolized in the liver and excreted primarily in urine.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for vasicine are documented in preclinical studies. The compound is generally well-tolerated at therapeutic doses. Common adverse effects may include mild gastrointestinal disturbances. High doses may cause central nervous system effects. The compound should be used with caution in patients with known hypersensitivity to quinazoline alkaloids. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References |
Duraipandiyan V, Al-Dhabi NA, Balachandran C, Ignacimuthu S, Sankar C, Balakrishna K. Antimicrobial, antioxidant, and cytotoxic properties of vasicine acetate synthesized from vasicine isolated from Adhatoda vasica L. Biomed Res Int. 2015;2015:727304.
|
| Additional Infomation |
Vasicine has reportedly been found in Anisotes trisulcus, Galega lindblomii, and other organisms with available data.
Vasicine (peganine) is a quinazoline alkaloid from Adhatoda vasica and Peganum harmala with bronchodilator, expectorant, anti-inflammatory, antimicrobial, and antioxidant activities. It has been used in traditional medicine for the treatment of respiratory disorders including asthma, bronchitis, and cough. The compound's bronchodilator and expectorant effects make it valuable for respiratory conditions. It has been studied in preclinical and clinical research for its potential in respiratory medicine. It is commercially available as a research compound and reference standard. |
| Molecular Formula |
C11H12N2O
|
|---|---|
| Molecular Weight |
188.23
|
| Exact Mass |
188.094
|
| CAS # |
6159-55-3
|
| Related CAS # |
Vasicine hydrochloride;7174-27-8;(±)-Vasicine;6159-56-4
|
| PubChem CID |
667496
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1124
|
| Boiling Point |
373.8±52.0 °C at 760 mmHg
|
| Melting Point |
211.5°C
|
| Flash Point |
179.9±30.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.5850
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
264
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O[C@H]1CCN2C1=NC3=C(C=CC=C3)C2
|
| InChi Key |
YIICVSCAKJMMDJ-SNVBAGLBSA-N
|
| InChi Code |
InChI=1S/C11H12N2O/c14-10-5-6-13-7-8-3-1-2-4-9(8)12-11(10)13/h1-4,10,14H,5-7H2/t10-/m1/s1
|
| Chemical Name |
(R)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol
|
| Synonyms |
Vasicine l-Vasacine l-Peganine Peganin (-)-Linarine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~442.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3126 mL | 26.5632 mL | 53.1265 mL | |
| 5 mM | 1.0625 mL | 5.3126 mL | 10.6253 mL | |
| 10 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA